EB-Haus Austria

Name

EB-Haus Austria

Legal name

DEBRA Austria - Schmetterlingskinder (Hilfe bei Epidermolysis bullosa)

Website

https://eb-haus.org

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

EB-Haus Austria is a nonprofit medical expertise center in Salzburg that provides specialized outpatient care, scientific and clinical research, and training for Epidermolysis Bullosa patients and clinicians, operating as a project of patient organization DEBRA Austria.

Ownership category

akta.pro rank

Product category

Rare Disease Specialty Clinic

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Professional, Scientific, and Technical Services (541), Medical and Diagnostic Laboratories (6215)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

akta.pro secondary industry

Clinical Research Ethics & Human Subjects Protection Authorities (IRB/REC Oversight) (HLAJACAG)

Keywords

• Epidermolysis bullosa care
• Rare disease specialty clinic
• Butterfly children treatment
• Dermatology wound care
• Clinical research EB

Headquarters

HQ city

Salzburg

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Donations and charitable funding: EB-Haus Austria is a nonprofit project of DEBRA Austria. It is entirely funded through donations, charitable contributions, and fundraising activities. The organization does not charge patients for medical services. DEBRA Austria collects donations via its Erste Bank account (IBAN: AT02 2011 1800 8018 1100) and an online donation form. DEBRA Austria is registered as a charitable association (ZVR 412404499) pursuing exclusively and directly the philanthropic purpose of promoting well-being of people with EB and advancing scientific research and education in EB.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

EB-Haus Austria is a nonprofit expertise center and specialty clinic for Epidermolysis Bullosa (EB), a rare genetic skin disorder. It delivers multidisciplinary outpatient care, scientific basic research, clinical trials, and EB-specific training for medical professionals and patients. The center operates as a project of DEBRA Austria at the University Clinic for Dermatology and Allergology on the Salzburg University Hospital campus, serving all EB subtypes (EBS, JEB, DEB, Kindler EB).

Product overview

EB-Haus Austria operates as a specialized medical expertise center for Epidermolysis bullosa (EB), organized into four interconnected service units: the Ambulanz (Outpatient Clinic) provides direct patient care; Forschung (Research) conducts scientific basic research; Klinische Forschung (Clinical Research) runs clinical trials for new treatments; and Akademie (Academy) delivers EB-specific education. Supporting these core services is the EB Handbook, a comprehensive educational resource available in multiple languages covering disease information, treatment guidance, and daily living management for various EB subtypes including EBS, DEB, JEB, and Kindler EB. The organization functions as a project of DEBRA Austria and is located at Salzburg University Hospital.

Differentiator

Problem solved

Functional benefit

Products and services

• Ambulanz (Outpatient Clinic) Specialized outpatient clinic providing free multidisciplinary medical care for patients with Epidermolysis Bullosa (all subtypes: EBS, JEB, DEB, Kindler EB). Staffed by specially trained physicians, nurses, and therapists offering wound care, pain management, genetic diagnostics, anesthesia protocols, nutritional counseling, and skin cancer monitoring.
• Forschung (Research) Scientific basic research focused on understanding and finding treatments for Epidermolysis Bullosa, working toward alleviation and cure. Active research areas include genetic diagnostics, stem cell therapy, and drug repurposing.
• Klinische Forschung (Clinical Research) Clinical research division conducting clinical trials and testing new treatment methods for Epidermolysis Bullosa patients. Provides patients access to experimental therapies and contributes to advancing evidence-based EB treatments.
• Akademie (EB-Akademie / Academy) EB-specific education and training for medical professionals and patients. Manages the international EB-Clinet network for global expert collaboration. Offers Aus- & Weiterbildung (advanced training and continuing education) programs for specialists and affected individuals.
• EB Handbook (EB-Handbuch) Comprehensive handbook providing detailed information about Epidermolysis Bullosa including disease information, treatment, accompanying symptoms, daily life management, psychology and social aspects, and newborn care. Available in German, English, Spanish, and Italian.

Quantifiable outcome

• 20 years of continuous operation and care provision
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Partnerships

Five partnerships are on record, tiered minor, primary and core.

• Seebühne Seeham (Theaterverein Die Seebühne Seeham)minorGTM or Marketing Partner · 1 January 2026The Seebühne Seeham theater association has performed annual summer theater productions for 20 years, donating all proceeds to DEBRA Austria / EB-Haus Austria. In June 2026, the theater was awarded the 'Schmetterlings-Award' (Butterfly Award) by DEBRA Austria for this sustained commitment. Productions include 'Ein Jedermann' in July 2026.
• Coca-Cola (Inclusion Run by Coca-Cola)minorGTM or Marketing Partner · 1 January 2026Coca-Cola organizes the 'One Mile For A Smile Inclusion Run' annually in Salzburg's Volksgarten. EB-Haus Austria / DEBRA Austria participates as a team (20 runners in 2026) to raise awareness for 'Schmetterlingskinder' and disability inclusion. Coca-Cola provides the platform and sponsorship for the inclusion event.
• DEBRA AustriaprimaryStrategic or Co-development PartnerDEBRA Austria is the parent patient organization that founded and wholly funds EB-Haus Austria. DEBRA Austria is a registered charitable association (ZVR 412404499) with its purpose being the promotion of well-being of people with EB and the advancement of scientific research in EB. DEBRA Austria manages all donations, fundraising, and governance for EB-Haus Austria.
• EB-Clinet (International Clinical Network)coreStrategic or Co-development PartnerEB-Clinet is an international medical network for EB clinical care and research. EB-Haus Austria is the Austrian hub of EB-Clinet, and the EB-Akademie manages the international network connections. The network connects EB expertise centers globally for shared learning, research collaboration, and clinical best practices.
• Universitätsklinik für Dermatologie und Allergologie, Uniklinikum Salzburg (University Clinic of Dermatology and Allergology, Salzburg University Hospital)primaryStrategic or Co-development PartnerEB-Haus Austria is affiliated with the University Clinic for Dermatology and Allergology at the Salzburg University Hospital (Landeskrankenhaus Salzburg). Prof. Johann Bauer serves as the clinic director and was formerly research leader at EB-Haus Austria. This affiliation enables clinical research translation and academic oversight of the center's medical operations.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Abeona Therapeutics: Clinical-stage biotech developing EB-101, an autologous cell therapy for recessive dystrophic EB. Comparable as an emerging EB therapeutic company that depends on specialist EB centers for clinical trial execution.
• Krystal Biotech: Commercial biotech that developed Vyjuvek, the first FDA-approved topical gene therapy for dystrophic EB. Relevant as an emerging EB therapeutic player that increasingly interacts with EB centers like EB-Haus Austria as clinical trial and treatment sites.

Direct peers

• DEBRA International: Umbrella patient organization for EB worldwide and parent of national DEBRA groups including DEBRA Austria. Highly comparable in mission (patient advocacy, research funding, EB community) and structurally connected to EB-Haus Austria via DEBRA Austria.
• Children's Hospital Colorado EB Clinic: A US-based specialized EB clinic with multidisciplinary care and clinical trial participation. Comparable in patient population, scope of services, and academic-hospital affiliation.
• Stanford EB Center (Stanford Medicine): US academic medical center running an EB specialty clinic and research program. Comparable as a university-hospital-affiliated EB center of excellence with combined clinical care, research, and training activities.
• EB Research Partnership (EBRP): US-based nonprofit funding EB research and coordinating multi-center initiatives. Comparable mission and funding model (donations, research grants) and operates as a peer organization for EB research and patient support.
• London EB Centre (Guy's and St Thomas' NHS Foundation Trust): A leading UK EB clinical and research center within a major academic hospital system. Directly comparable as a specialized EB care and research site with multidisciplinary team and clinical trial capacity, similar in scale and scope to EB-Haus Austria.
• EB House Germany (EB-Haus Deutschland, Freiburg): The German counterpart EB center of excellence at the University Medical Center Freiburg, operating under the same DEBRA-family model with outpatient clinic, research, and academy units. Directly comparable structure, funding model, and patient population as EB-Haus Austria.
• Phoenix Children's Hospital EB Clinic: A US pediatric EB clinic of excellence participating in multi-center research consortia. Comparable as a specialty EB clinic with clinical trial activity and family-centered multidisciplinary care.
• University of Minnesota EB Center: Academic EB research and clinical center with a long history in EB gene therapy and translational research. Comparable as a research-active EB center with bench-to-bedside focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/schmetterlingskinder
• LinkedInlinkedin.com/company/eb-haus-austria

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EB-Haus Austria